DOC

1. 2026-10-19issueIssued emergency
2. 2026-10-19issueIssued info_card
3. 2026-09-07srcEffect of Hallucinogens on Unconditioned Behavior.
4. 2026-09-07srcOpioid analgesic drugs and serotonin toxicity (syndrome): mechanisms, animal models, and links to clinical effects
5. 2026-09-07srcBehavioral and neurochemical pharmacology of six psychoactive substituted phenethylamines: mouse locomotion, rat drug discrimination and in vitro receptor and transporter binding and function
6. 2026-09-07srcDifficulties interpreting concentrations in fatal cases: example of 2,5-dimethoxy-4-chloroamphetamine.
7. 2026-09-07srcAnalysis of 2,5-dimethoxy-amphetamines and 2,5-dimethoxy-phenethylamines aiming their determination in biological matrices: a review.
8. 2026-09-07srcChronic administration of serotonergic antidepressants attenuates the subjective effects of LSD in humans.
9. 2026-09-07src2,5-dimethoxy-4-chloroamphetamine, a LSD-like designer drug: Clinical and analytical documentation of non-fatal exposure in five patients.
10. 2026-09-07src2,5-Dimethoxyamphetamine-derived designer drugs: studies on the identification of cytochrome P450 (CYP) isoenzymes involved in formation of their main metabolites and on their capability to inhibit CYP2D6.
11. 2026-09-07src1-(2,5-Dimethoxy-4-iodophenyl)-2-aminopropane (DOI): From an Obscure to Pivotal Member of the DOX Family of Serotonergic Psychedelic Agents - A Review.
12. 2026-09-07srcIdentification of 5-HT2A receptor signaling pathways associated with psychedelic potential
13. 2026-09-07srcCardiac Consequences Associated with Psychedelic Use: A Systematic Review of LSD, MDMA, and 5-HT2B-Mediated Valvular Heart Disease.
14. 2026-09-07srcA fatal intoxication of 2,5-dimethoxy-4-chloroamphetamine: a case report.
15. 2026-09-07srcFirst case report of recreational use of 2,5-dimethoxy-4-chloroamphetamine confirmed by toxicological screening.
16. 2026-09-07srcThe Synthesis of Some Analogs of the Hallucinogen 1-(2,5-Dimethoxy-4-methylphenyl)-2-aminopropane (DOM).
17. 2026-09-07srcPsychedelics and the human receptorome
18. 2026-09-07src3,4-methylenedioxymethamphetamine (MDMA) induces fenfluramine-like proliferative actions on human cardiac valvular interstitial cells in vitro.
19. 2026-09-07srcComparisons of hallucinogenic phenylisopropylamine binding affinities at cloned human 5-HT2A, 5-HT2B and 5-HT2C receptors.
20. 2026-09-07srcFederal Register Proposed Rule: Placement of DOI and DOC in Schedule I
21. 2026-09-07srcFederal Register Proposed Rule: Second NPRM for DOI and DOC Schedule I Placement
22. 2026-09-07srcNCATS Inxight Drugs: DOC (2,5-dimethoxy-4-chloroamphetamine)
23. 2026-09-07srcPiHKAL: A Chemical Love Story (#64 DOC)
24. 2026-09-07srcCritical Review Report: DOC (4-Chloro-2,5-dimethoxyamfetamine)
25. 2026-09-04issueIssued emergency
26. 2026-09-04issueIssued info_card
27. 2026-09-04issueIssued notice
28. 2026-06-04proposal29 value proposals approved togetherone review action inferred from a shared reviewer and instant — the graph records one activity per proposal
29. 2026-06-04publicationPublication — backfill
30. 2026-04-24revisionRevision 1
31. 2026-04-24absenceSearched ClinicalTrials.gov for "DOC 4-chloro-2,5-dimethoxyamphetamine" — no results
32. 2026-04-24genGeneration — pipeline-v5pipeline-v5
33. 2026-04-24rungeneration run

The same entries, as forms: six forms.